Alzheimer’s drug development pipeline: Promising therapies, pharma investment drive momentum in clinical trials

May 25, 2023

More than 6 million Americans are living with Alzheimer’s disease, a staggering number that’s expected to double within the next 30 years.

Decades-old allergy drug shows potential for treating liver complications in rare genetic disease
A common antihistamine may offer hope for patients with a rare genetic disease that can lead to severe liver damage and ultimately require transplantation, according to new research from Rutgers Health.
Phase III trial finds trastuzumab emtansine improves long-term survival in HER2 breast cancer
In patients with high-risk HER2-positive breast cancer, post-surgery, or adjuvant, treatment with trastuzumab emtansine (T-DM1) reduced the long-term risk of death or invasive disease by 46% and improved survival compared to trastuzumab alone, according to the final results of the Phase III KATHERINE clinical trial led by researchers from the University of Pittsburgh and UPMC Hillman Cancer Center.
Exploring novel deep learning-based models for cancer histopathology image analysis
Histopathological evaluation of tumor specimens has long been essential in diagnosing breast cancer and guiding clinical decision-making. However, one of the key challenges in routine diagnostics includes the inter-observer and inter-lab variabilities present in the assessment of prognostic markers that could lead to under- and over-treatment of patients.
Pediatrics study examines the diagnostic potential of microbial cell-free DNA testing
Ear, nose, and throat (ENT) infections are one of the most common reasons for prescribing antibiotics to children. Although some ENT infections can be simple to identify and diagnose, others are more severe and require immediate attention and care.
Combining ctDNA and genomic profiling predicts cancer relapse and treatment response
Researchers from Iwate Medical University and Tohoku University have revealed that it is possible to predict cancer relapse and treatment response by measuring circulating tumor DNA (ctDNA), in tandem with data from comprehensive genomic profiling (CGP). Their study is published in the journal Cancer Science.

Alzheimer’s drug development pipeline: Promising therapies, pharma investment drive momentum in clinical trials

Recent Posts

JUST IN